SIM
ESPR

Spark Investment Management’s Esperion Therapeutics ESPR Stock Holding History

Spark Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,100
Closed -$318K – 138
2020
Q1 		$318K Hold
10,100
– – 0.17% 185
2019
Q4 		$602K Sell
10,100
-54,800
-84% -$2.46M 0.07% 324
2019
Q3 		$2.38M Sell
64,900
-189,800
-75% -$7.52M 0.3% 107
2019
Q2 		$11.8M Sell
254,700
-136,200
-35% -$6.4M 0.82% 21
2019
Q1 		$15.7M Buy
390,900
+163,800
+72% +$7.35M 0.73% 30
2018
Q4 		$10.4M Buy
227,100
+103,100
+83% +$4.97M 0.72% 24
2018
Q3 		$5.5M Buy
124,000
+43,400
+54% +$1.99M 0.32% 98
2018
Q2 		$3.16M Buy
80,600
+37,200
+86% +$1.88M 0.19% 166
2018
Q1 		$3.14M Buy
+43,400
New +$3.19M 0.2% 164
2014
Q1 		– Sell
-25,000
Closed -$342K – 691
2013
Q4 		$342K Sell
25,000
-10,400
-29% -$151K 0.06% 406
2013
Q3 		$667K Buy
+35,400
New +$595K 0.15% 198

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Spark Investment Management's ESPR Position: Q2 2020 in Review

Spark Investment Management sold out of Esperion Therapeutics (ESPR) in Q2 2020, closing a stake of 10,100 shares — an estimated $318K sold.

Spark Investment Management first reported a position in ESPR in Q3 2013 and held it in 11 quarters. The position peaked at $15.7M in Q1 2019. 182 funds tracked by Wall St. Rank hold ESPR as of Q2 2020.

  • Spark Investment Management reported no remaining Esperion Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 10,100 Esperion Therapeutics shares in Q2 2020, an estimated $318K.
  • Spark Investment Management first reported a position in Esperion Therapeutics in Q3 2013 and held it in 11 quarters.
  • Spark Investment Management's Esperion Therapeutics position peaked at $15.7M in Q1 2019.
  • 182 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.